• GMP Medicine Griseofulvin Tablets for The Treatment of Tinea
  • GMP Medicine Griseofulvin Tablets for The Treatment of Tinea
  • GMP Medicine Griseofulvin Tablets for The Treatment of Tinea
  • GMP Medicine Griseofulvin Tablets for The Treatment of Tinea
  • GMP Medicine Griseofulvin Tablets for The Treatment of Tinea

GMP Medicine Griseofulvin Tablets for The Treatment of Tinea

Application: Internal Medicine
Usage Mode: For oral administration
Suitable for: Elderly, Children, Adult
State: Solid
Shape: Tablet
Type: Organic Chemicals
Samples:
US$ 0/box 1 box(Min.Order)
| Request Sample
Customization:

360° Virtual Tour

Diamond Member Since 2015

Suppliers with verified business licenses

Manufacturer/Factory, Trading Company

Basic Info.

Model NO.
AMC12020-01
Pharmaceutical Technology
Chemical Synthesis
Registration
Available
OEM/ODM
Support
Shelf-Life
3 Years
Transport Package
10′ Sx10/Box
Specification
500mg
Trademark
Medipharm, OEM
Origin
China
HS Code
3004909099
Production Capacity
1000000 Boxes/Month

Product Description

GMP Medicine Griseofulvin Tablets for The Treatment of Tinea
Indications:

Griseofulvin is primarily indicated in conditions like Dermatophytic infections, Fungal infection, Parkinson's disease.

Contra-indications:
This drug is contraindicated in patients with porphyria, hepatocellular failure, and in individuals with a history of hypersensitivity to griseofulvin.

Adverse Effects:
Adverse reactions of griseofulvin are uncommon. Nausea, diarrhea, headache, skin eruptions and photosensitivity are occasionally observed. Hepatotoxicity and neurological side effects may rarely occur.

Drug Interactions:
Griseofulvin can interact with blood thinners and birth control pills.

Precautions & Warning:
*Caution should be exercised in patients with history of liver disease, porphyria, lupus, or history of alcohol abuse, any allergy, who are taking other medications, during pregnancy and breastfeeding.
* Avoid exposure to sunlight.

Use in Pregnancy and Nursing Mothers:
Griseofulvin is assigned to pregnancy category C. Animal studies have revealed evidence of embryotoxicity and teratogenicity. There are no controlled data in human pregnancies; however, there are reports of congenital anomalies, including cases of conjoined twins in two women, as well as increased risk of spontaneous abortion. The manufacturer considers griseofulvin use to be contraindicated during pregnancy.There are no data on the excretion of griseofulvin into human milk.

Treatment/antidote in The Event of Overdose:
Treatment is symptomatic and supportive. There is no specific antidote for treatment of griseofulvin intoxication.

Storage instructions:
Store below 25 degrees celsius. Protect from moisture. Keep out of reach of children.

Validity: Three Years


Other Specification:
AMC12020-01 GRISEOFULVIN TABLET 500MG,10*10/BOX
AMC12020-02 GRISEOFULVIN TABLET 500MG,1000'S/JAR
AMC12020-03 GRISEOFULVIN TABLET 500MG,20'S/BLISTER/BOX
AMC12020-04 GRISEOFULVIN TABLET 250MG,10*10/BOX
AMC12020-05 GRISEOFULVIN TABLET 125MG,10'S*10/BOX
AMC12020-06 GRISEOFULVIN TABLET 250MG,1000'S/JAR


GMP Medicine Griseofulvin Tablets for The Treatment of TineaGMP Medicine Griseofulvin Tablets for The Treatment of TineaGMP Medicine Griseofulvin Tablets for The Treatment of TineaGMP Medicine Griseofulvin Tablets for The Treatment of TineaGMP Medicine Griseofulvin Tablets for The Treatment of TineaGMP Medicine Griseofulvin Tablets for The Treatment of Tinea

 



 




 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now